| Chronic kidney disease K Kalantar-Zadeh, TH Jafar, D Nitsch, BL Neuen, V Perkovic The Lancet, 2021 | 799 | 2021 |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ... The lancet Diabetes & endocrinology 7 (11), 845-854, 2019 | 782 | 2019 |
| Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta‐analysis T Toyama, BL Neuen, M Jun, T Ohkuma, B Neal, MJ Jardine, ... Diabetes, Obesity and Metabolism 21 (5), 1237-1250, 2019 | 281 | 2019 |
| Chronic kidney disease and the global NCDs agenda BL Neuen, SJ Chadban, AR Demaio, DW Johnson, V Perkovic BMJ global health 2 (2), e000380, 2017 | 268 | 2017 |
| Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS Program BL Neuen, T Ohkuma, B Neal, DR Matthews, D De Zeeuw, KW Mahaffey, ... Circulation 138 (15), 1537-1550, 2018 | 257 | 2018 |
| Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials TNDPHRSG the SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists Consortium The Lancet 400 (10365), 1788-1801, 2022 | 228 | 2022 |
| Sodium‐glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis C Arnott, Q Li, A Kang, BL Neuen, S Bompoint, CSP Lam, A Rodgers, ... Journal of the American Heart Association 9 (3), e014908, 2020 | 222 | 2020 |
| Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey AK Bello, A Levin, M Lunney, MA Osman, F Ye, GE Ashuntantang, ... bmj 367, 2019 | 215 | 2019 |
| Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials BL Neuen, M Oshima, R Agarwal, C Arnott, DZ Cherney, R Edwards, ... Circulation 145 (19), 1460-1470, 2022 | 149 | 2022 |
| Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis JT Ha, BL Neuen, LP Cheng, M Jun, T Toyama, MP Gallagher, MJ Jardine, ... Annals of internal medicine 171 (3), 181-189, 2019 | 144 | 2019 |
| Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a posthoc analysis from the CREDENCE trial M Oshima, BL Neuen, JW Li, V Perkovic, DM Charytan, D de Zeeuw, ... Journal of the American Society of Nephrology 31 (12), 2925-2936, 2020 | 119 | 2020 |
| Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program BL Neuen, T Ohkuma, B Neal, DR Matthews, D De Zeeuw, KW Mahaffey, ... Journal of the American Society of Nephrology 30 (11), 2229-2242, 2019 | 118 | 2019 |
| Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial BL Neuen, M Oshima, V Perkovic, R Agarwal, C Arnott, G Bakris, ... European heart journal 42 (48), 4891-4901, 2021 | 101 | 2021 |
| Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial M Oshima, BL Neuen, MJ Jardine, G Bakris, R Edwards, A Levin, ... The Lancet Diabetes & Endocrinology 8 (11), 903-914, 2020 | 90 | 2020 |
| Peritoneal dialysis use and practice patterns: an international survey study Y Cho, AK Bello, A Levin, M Lunney, MA Osman, F Ye, GE Ashuntantang, ... American Journal of Kidney Diseases 77 (3), 315-325, 2021 | 88 | 2021 |
| Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes JW Li, B Neal, V Perkovic, D de Zeeuw, BL Neuen, C Arnott, R Simpson, ... Kidney international 98 (3), 769-777, 2020 | 87 | 2020 |
| Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease Z Zhou, MJ Jardine, Q Li, BL Neuen, CP Cannon, D De Zeeuw, ... Stroke, 2021 | 79 | 2021 |
| Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial N Ye, MJ Jardine, M Oshima, C Hockham, HJL Heerspink, R Agarwal, ... Circulation 143 (18), 1735-1749, 2021 | 69 | 2021 |
| Predictors of patency after balloon angioplasty in hemodialysis fistulas: a systematic review BL Neuen, R Gunnarsson, AC Webster, RA Baer, J Golledge, ML Mantha Journal of Vascular and Interventional Radiology 25 (6), 917-924, 2014 | 63 | 2014 |
| Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial T Sen, J Li, BL Neuen, B Neal, C Arnott, CR Parikh, SG Coca, V Perkovic, ... Diabetologia 64 (10), 2147-2158, 2021 | 53 | 2021 |
Vlado PerkovicDean of Medicine, University of New South Wales; Professorial Fellow, The George Institute在 george.org.au 的电子邮件经过验证
